Status:
COMPLETED
Proton Beam Re-Irradiation in Thoracic Cancers
Lead Sponsor:
University of Washington
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Metastatic Malignant Neoplasm in the Lung
Recurrent Disease
Eligibility:
All Genders
19+ years
Phase:
NA
Brief Summary
This pilot clinical trial studies proton beam radiation therapy in treating patients with thoracic cancer that has come back and have received prior radiation therapy. Proton beam radiation therapy us...
Detailed Description
PRIMARY OBJECTIVES: I. To assess the grade 3 toxicity associated with thoracic re-irradiation with proton therapy, with prospectively applied normal organ radiation dose limits. SECONDARY OBJECTIVES...
Eligibility Criteria
Inclusion
- Women of child-bearing age must have a negative pregnancy test
- Patients must have received prior radiation treatment to the chest; records of prior radiation treatment must be available
- Patients must have received prior chest radiation at least 3 months prior to enrollment in this trial; radiation treatment to other body sites not overlapping with current radiation fields are allowed within the 3 months period (example, brain radiation is allowed)
- Patients must have a prior diagnosis of cancer inside the thoracic cavity; both primary thoracic malignancies (such as lung cancer) as well as metastatic lesions (such as metastatic breast cancer or colorectal cancer to the lungs) are allowed; patient must have pathologic confirmation of the recurrent thoracic tumor, or have an enlarging thoracic mass (as seen on two computed tomography \[CT\] scans at least 6 weeks apart, with either a \> 25% or \> 5 mm increase in longest dimension)
- Patients must have a life expectancy of \> 6 months
- Patients must have measurable disease to be treated with proton radiation (minimum tumor dimension at least 10 mm on CT imaging)
- Patients should have either non-metastatic cancer of the thorax, or metastatic cancer to the thorax and candidate for definitive radiation dose to the thoracic tumor (not palliative intent), tumor radiation dose to at least BED2Gy 60 Gy
- Patients must be able to receive proton radiation treatment
- All stages of cancer are eligible
- There are no limits on prior therapy; patients are allowed to have prior chemotherapy and surgery; patients are allowed to have concurrent chemotherapy with radiation treatment; patients are allowed to have chemotherapy or surgery after radiation treatment
- Patients are allowed to be on another study concurrent with this protocol
- Ability to understand and the willingness to sign a written informed consent document
Exclusion
- Patients who have never received radiation to the chest
- Patients who received radiation to the chest within the past 3 months (in a region that overlaps with current radiation fields)
- Patients with life expectancy \< 6 months
- Pregnant women
- Patients unable to provide informed consent
- Prisoners
Key Trial Info
Start Date :
September 9 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 7 2017
Estimated Enrollment :
6 Patients enrolled
Trial Details
Trial ID
NCT02204761
Start Date
September 9 2014
End Date
September 7 2017
Last Update
November 20 2018
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Seattle, Washington, United States, 98109
2
ProCure Proton Therapy Center-Seattle
Seattle, Washington, United States, 98133